KeifeRx
Developing novel and optimized Kinase Inhibitors for the treatment of neurodegenerative and immune diseases
Our Focus
KeifeRx is dedicated to improving the treatment of neurodegenerative and immune diseases and bringing relief to the millions of people worldwide who are impacted by these debilitating, life-diminishing conditions.
Our Science
KeifeRx seeks to leverage mechanisms of action inherent to Kinase Inhibitors which thus far have been underexplored: the ability to penetrate the brain, induce autophagy, and enable the bulk disposal of disease-causing toxic proteins to treat neurodegenerative diseases, and the ability to target mast cells and simultaneously modulate peripheral and central immunity, providing therapeutic potential for an array of immune diseases.
These properties offer the potential to significantly improve upon current neurodegenerative and immune disease treatments, which are primarily palliative and offer minimal and temporary benefits due to their inability to adequately eliminate toxic proteins and mitigate inflammation.
Our Pipeline
KeifeRx is currently investigating its Kinase Inhibitor formulations in neurodegenerative diseases, including Alzheimer’s disease (AD) and Mild Cognitive Impairment (MCI), and movement disorders, including Lewy Body Dementia (LBD), Amyotrophic Lateral Sclerosis (ALS) and Huntington’s disease. Additionally, KeifeRx is advancing novel Kinase Inhibitors targeting inflammatory diseases, including mast cell activated syndromes (MCAS), Lyme disease, and Urticaria, as well as neuro-inflammatory conditions that are features of neurodegeneration.
News
MAR 27, 2024
BUSINESSWIRE
KeifeRx Announces the Appointments of Dan Feehan and Alison Finger to Board of Directors
JAN 8, 2024
PR NEWSWIRE
KeifeRx Expands Exclusive Licensing Agreement with Georgetown University to Include Multiple Disease Indications for Portfolio of Novel Tyrosine Kinase Inhibitors
FEB 14, 2023
PR NEWSWIRE
KeifeRx Appoints Garrett Vygantas, MD, MBA, to Board of Directors
JANUARY 26, 2022
FOX BUSINESS
Keiferx CEO on new method for treating Alzheimer’s, neurodegenerative disease
JANUARY 19, 2022
THE BIO REPORT
Disposing Toxic Proteins to Treat Neurodegenerative Diseases
Recent News
Item Title
This is a paragraph area where you can include any information you’d like. It’s an opportunity to tell a story about the business or describe a special service or product it offers. You can use this space to share the company history or highlight a particular feature that sets it apart from competitors.
Let the writing speak for itself. Keep a consistent tone and voice throughout the website to stay true to the brand image and give visitors a taste of the company’s values and personality.
Item Title
This is a paragraph area where you can include any information you’d like. It’s an opportunity to tell a story about the business or describe a special service or product it offers. You can use this space to share the company history or highlight a particular feature that sets it apart from competitors.
Let the writing speak for itself. Keep a consistent tone and voice throughout the website to stay true to the brand image and give visitors a taste of the company’s values and personality.
Item Title
This is a paragraph area where you can include any information you’d like. It’s an opportunity to tell a story about the business or describe a special service or product it offers. You can use this space to share the company history or highlight a particular feature that sets it apart from competitors.
Let the writing speak for itself. Keep a consistent tone and voice throughout the website to stay true to the brand image and give visitors a taste of the company’s values and personality.
